Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment
In patients with advanced stage lung disease, it is beneficial to evaluate candidacy for immunotherapy without invasive biopsy testing. Lou et al performed a concordance study to evaluate formalin fixed cell blocks compared to lung tumor resections using a PD-L1 22C3 IHC pharmDx™ assay and found strong concordance between pathologists and HALO image analysis software. Future research will focus on clinical validation by assessing the clinical benefit from immunotherapy following PD-L1 immunohistochemistry on cytology specimens.
Hewitt SL, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, Burke S, Garcon F, Mishra A, Gurumurthy S, Watkins A, Arnold K, Moynihan J, Clancy-Thompson E, Mulgrew K, Adjei G, Deschler K, Potz D, Moody G, Leinster DA, Novick S, Sulikowski M, Bagnall CJ, Martin P, Lapointe J-M, Si H, Morehouse CA, Sedic M, Wilkinson RW, Herbst R, Frederick JP, Luheshi N
Clinical Cancer Research | First published December 2020 | DOI https://doi.org/10.1158/1078-0432.CCR-20-0472